Loading
Latest filing published 21 Jan 2016 for CASI Pharmaceuticals, Inc.. Read the official filing
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
This profile gathers the share dealings of Ken Keyong Ren in CASI Pharmaceuticals, Inc. Altogether 4 filings, all relating to 19 January 2016.
Purchases make up the whole of the open-market record (4 purchases). The totals do not cover 4 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
Across 4 purchases, this insider has always bought alone, with no colleague buying within 30 days.
On 21 January 2016 came the latest disclosure, an open-market purchase in CASI Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations